1262 related articles for article (PubMed ID: 28486906)
21. Factors affecting toxicity and efficacy of polymeric nanomedicines.
Igarashi E
Toxicol Appl Pharmacol; 2008 May; 229(1):121-34. PubMed ID: 18355886
[TBL] [Abstract][Full Text] [Related]
22. Nanotechnology in Drug Delivery: Safety and Toxicity Issues.
Jain K; Mehra NK; Jain NK
Curr Pharm Des; 2015; 21(29):4252-61. PubMed ID: 26323425
[TBL] [Abstract][Full Text] [Related]
23. Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy.
Rahman M; Akhter S; Ahmad J; Ahmad MZ; Beg S; Ahmad FJ
Expert Opin Drug Deliv; 2015 Apr; 12(4):635-52. PubMed ID: 25439967
[TBL] [Abstract][Full Text] [Related]
24. Medical and dental applications of nanomedicines.
Kavoosi F; Modaresi F; Sanaei M; Rezaei Z
APMIS; 2018 Oct; 126(10):795-803. PubMed ID: 30264432
[TBL] [Abstract][Full Text] [Related]
25. Insights into Active Targeting of Nanoparticles in Drug Delivery: Advances in Clinical Studies and Design Considerations for Cancer Nanomedicine.
Pearce AK; O'Reilly RK
Bioconjug Chem; 2019 Sep; 30(9):2300-2311. PubMed ID: 31441642
[TBL] [Abstract][Full Text] [Related]
26. Nanomedicines: addressing the scientific and regulatory gap.
Tinkle S; McNeil SE; Mühlebach S; Bawa R; Borchard G; Barenholz YC; Tamarkin L; Desai N
Ann N Y Acad Sci; 2014 Apr; 1313():35-56. PubMed ID: 24673240
[TBL] [Abstract][Full Text] [Related]
27. Nanomedicines for kidney diseases.
Williams RM; Jaimes EA; Heller DA
Kidney Int; 2016 Oct; 90(4):740-5. PubMed ID: 27292222
[TBL] [Abstract][Full Text] [Related]
28. The nanomedicines alliance: an industry perspective on nanomedicines.
Malinoski FJ
Nanomedicine; 2014 Nov; 10(8):1819-20. PubMed ID: 25038497
[TBL] [Abstract][Full Text] [Related]
29. Nanomedicines: The magic bullets reaching their target?
Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
[TBL] [Abstract][Full Text] [Related]
30. Overview of the blood compatibility of nanomedicines: A trend analysis of in vitro and in vivo studies.
Urbán P; Liptrott NJ; Bremer S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1546. PubMed ID: 30556649
[TBL] [Abstract][Full Text] [Related]
31. Critical considerations for targeting colorectal liver metastases with nanotechnology.
Arshad U; Sutton PA; Ashford MB; Treacher KE; Liptrott NJ; Rannard SP; Goldring CE; Owen A
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Mar; 12(2):e1588. PubMed ID: 31566913
[TBL] [Abstract][Full Text] [Related]
32. Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.
Balasubramanian V; Liu Z; Hirvonen J; Santos HA
Adv Healthc Mater; 2018 Jan; 7(1):. PubMed ID: 28570787
[TBL] [Abstract][Full Text] [Related]
33. Nanomedicines accessible in the market for clinical interventions.
Gadekar V; Borade Y; Kannaujia S; Rajpoot K; Anup N; Tambe V; Kalia K; Tekade RK
J Control Release; 2021 Feb; 330():372-397. PubMed ID: 33370576
[TBL] [Abstract][Full Text] [Related]
34. Advances and challenges in nanocarriers and nanomedicines for veterinary application.
Carvalho SG; Araujo VHS; Dos Santos AM; Duarte JL; Silvestre ALP; Fonseca-Santos B; Villanova JCO; Gremião MPD; Chorilli M
Int J Pharm; 2020 Apr; 580():119214. PubMed ID: 32165220
[TBL] [Abstract][Full Text] [Related]
35. Nanotechnology-based intelligent drug design for cancer metastasis treatment.
Gao Y; Xie J; Chen H; Gu S; Zhao R; Shao J; Jia L
Biotechnol Adv; 2014; 32(4):761-77. PubMed ID: 24211475
[TBL] [Abstract][Full Text] [Related]
36. Exploiting endocytosis for nanomedicines.
Akinc A; Battaglia G
Cold Spring Harb Perspect Biol; 2013 Nov; 5(11):a016980. PubMed ID: 24186069
[TBL] [Abstract][Full Text] [Related]
37. Nanodelivery systems for improved topical antimicrobial therapy.
Basnet P; Škalko-Basnet N
Curr Pharm Des; 2013; 19(41):7237-43. PubMed ID: 23489202
[TBL] [Abstract][Full Text] [Related]
38. Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography-Inductively Coupled Plasma-Mass Spectrometric Approach.
Neu HM; Alexishin SA; Brandis JEP; Williams AMC; Li W; Sun D; Zheng N; Jiang W; Zimrin A; Fink JC; Polli JE; Kane MA; Michel SLJ
Mol Pharm; 2019 Mar; 16(3):1272-1281. PubMed ID: 30676753
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic efficacy of nanomedicines for prostate cancer: An update.
Lakshmanan VK
Investig Clin Urol; 2016 Jan; 57(1):21-9. PubMed ID: 26966723
[TBL] [Abstract][Full Text] [Related]
40. [Development of Drug Delivery Technology and Nanomedicine by Using Gold Nanoparticles].
Ozeki T; Tagami T
Yakugaku Zasshi; 2021; 141(3):323-326. PubMed ID: 33642498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
